Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000655791 | SCV000777722 | uncertain significance | Spermatogenic failure 18; Ciliary dyskinesia, primary, 37 | 2022-07-15 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 222 of the DNAH1 protein (p.His222Gln). This variant is present in population databases (rs767198288, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with DNAH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 544594). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002534234 | SCV003749940 | uncertain significance | Inborn genetic diseases | 2022-12-13 | criteria provided, single submitter | clinical testing | The c.666C>A (p.H222Q) alteration is located in exon 5 (coding exon 4) of the DNAH1 gene. This alteration results from a C to A substitution at nucleotide position 666, causing the histidine (H) at amino acid position 222 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |